Every day in America, a tragic and silent crisis unfolds: between 17 and 44 veterans take their own lives. This is not merely a staggering statistic; it represents a catastrophic failure in our national standard of care for the men and women who have sacrificed the most for this country. While the mental health crisis in the United States continues to accelerate, the tools we provide our heroes have remained frozen in time. For veterans battling Post-Traumatic Stress Disorder (PTSD), the primary medications they are prescribed have not seen a significant innovation since the early 1990s.
We are currently asking our veterans to rely on a system that hasn’t evolved in over 35 years. For many, the “standard of care” has devolved into what a recent Wall Street Journal exposé called a “Combat Cocktail”—a dangerous practice where over 500,000 veterans are prescribed multiple psychiatric drugs simultaneously, despite internal warnings about the risks of polypharmacy. When 70% of patients do not achieve full remission with these traditional first-line treatments, it is clear that “more of the same” is a recipe for further loss.
At the Association for Prescription Psychedelics (APP), we believe that policymakers must no longer delay in addressing these unmet medical needs. The science has finally caught up to the urgency of the mission. Recent clinical data show that FDA-regulated prescription psychedelic medicines offer a level of efficacy previously thought impossible:
- Rapid Remission: 67% of patients with PTSD no longer met the diagnostic criteria for the disorder following just three MDMA-assisted therapy sessions.
- Significant Impact: 88% of patients in clinical trials experienced a clinically significant reduction in their symptoms.
These are not just numbers; they are lives restored. As Iraq War veteran Jonathan Lubecki powerfully shared, these breakthrough therapies can be the “sole reason that my son has a father instead of a folded flag.”
The time for a “wait and see” approach has passed. We are seeing a historic alignment in leadership: FDA Commissioner Marty Makary has labeled these medicines a top priority for expeditious review, and VA Secretary Doug Collins is actively coordinating with federal agencies to increase trial availability for veterans.
However, achieving safe and equitable access requires immediate and streamlined FDA and DEA coordination. We must ensure the review process is accelerated and the VA is fully prepared to implement these therapies the moment they launch. Every 11 minutes, we lose another fellow American to suicide. For the veteran community, every hour of bureaucratic delay is an hour they simply do not have. We owe them more than gratitude; we owe them the best that modern medicine has to offer.
